Nuevas alternativas en el tratamiento del cancer gástrico avanzado

Background: Chemotherapy improves survival in advanced gastric cancer. However the most active combinations have a high level of toxicity that limits their use. Aim: To assess the response, toxicity and survival of patients with advanced gastric cancer, treated with oxaliplatin plus 5-fluorouracil/l...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Garrido,Marcelo, Melgoza,Geraldine, Galindo,Héctor, Madrid,Jorge, Sánchez,César, Nervi,Bruno, Alvarez,Manuel, Orellana,Eric
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2007
Materias:	Antineoplastic combined chemotherapy protocols Órgano platinum compounds Stomach neoplasms
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007001100003
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872007001100003
record_format	dspace
spelling	oai:scielo:S0034-988720070011000032008-02-08Nuevas alternativas en el tratamiento del cancer gástrico avanzadoGarrido,MarceloMelgoza,GeraldineGalindo,HéctorMadrid,JorgeSánchez,CésarNervi,BrunoAlvarez,ManuelOrellana,Eric Antineoplastic combined chemotherapy protocols Órgano platinum compounds Stomach neoplasms Background: Chemotherapy improves survival in advanced gastric cancer. However the most active combinations have a high level of toxicity that limits their use. Aim: To assess the response, toxicity and survival of patients with advanced gastric cancer, treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4 chemotherapy). Material and methods: Patients with stage IVgastric cancer, according to the American Joint Committee on Cancer or with relapsed disease and functional capacity 0-2 of the South West Oncology Group, were included. FOLFOX-4 chemotherapy was used as first or second line treatment. The response to treatment and survival were assessed. Results: Between 2003 and 2006, 29 patients (median age 52.5 years, 69% males) were treated. FOLFOX-4 was given as first line treatment in 65% patients and as second line in 35%. There was a complete response in 4.6%, partial response in 68%, stable disease in 20.6% and progression in 6.8%. Toxicity was observed in 51% of patients, that was hematological and non hematological grade 3/4 in 14%. Median survival was 12.5 months. Conclusions: FOLFOX-4 chemotherapy was active in advanced gastric cancer and had a low level of toxicityinfo:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.135 n.11 20072007-11-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007001100003es10.4067/S0034-98872007001100003
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Antineoplastic combined chemotherapy protocols Órgano platinum compounds Stomach neoplasms
spellingShingle	Antineoplastic combined chemotherapy protocols Órgano platinum compounds Stomach neoplasms Garrido,Marcelo Melgoza,Geraldine Galindo,Héctor Madrid,Jorge Sánchez,César Nervi,Bruno Alvarez,Manuel Orellana,Eric Nuevas alternativas en el tratamiento del cancer gástrico avanzado
description	Background: Chemotherapy improves survival in advanced gastric cancer. However the most active combinations have a high level of toxicity that limits their use. Aim: To assess the response, toxicity and survival of patients with advanced gastric cancer, treated with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4 chemotherapy). Material and methods: Patients with stage IVgastric cancer, according to the American Joint Committee on Cancer or with relapsed disease and functional capacity 0-2 of the South West Oncology Group, were included. FOLFOX-4 chemotherapy was used as first or second line treatment. The response to treatment and survival were assessed. Results: Between 2003 and 2006, 29 patients (median age 52.5 years, 69% males) were treated. FOLFOX-4 was given as first line treatment in 65% patients and as second line in 35%. There was a complete response in 4.6%, partial response in 68%, stable disease in 20.6% and progression in 6.8%. Toxicity was observed in 51% of patients, that was hematological and non hematological grade 3/4 in 14%. Median survival was 12.5 months. Conclusions: FOLFOX-4 chemotherapy was active in advanced gastric cancer and had a low level of toxicity
author	Garrido,Marcelo Melgoza,Geraldine Galindo,Héctor Madrid,Jorge Sánchez,César Nervi,Bruno Alvarez,Manuel Orellana,Eric
author_facet	Garrido,Marcelo Melgoza,Geraldine Galindo,Héctor Madrid,Jorge Sánchez,César Nervi,Bruno Alvarez,Manuel Orellana,Eric
author_sort	Garrido,Marcelo
title	Nuevas alternativas en el tratamiento del cancer gástrico avanzado
title_short	Nuevas alternativas en el tratamiento del cancer gástrico avanzado
title_full	Nuevas alternativas en el tratamiento del cancer gástrico avanzado
title_fullStr	Nuevas alternativas en el tratamiento del cancer gástrico avanzado
title_full_unstemmed	Nuevas alternativas en el tratamiento del cancer gástrico avanzado
title_sort	nuevas alternativas en el tratamiento del cancer gástrico avanzado
publisher	Sociedad Médica de Santiago
publishDate	2007
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872007001100003
work_keys_str_mv	AT garridomarcelo nuevasalternativaseneltratamientodelcancergastricoavanzado AT melgozageraldine nuevasalternativaseneltratamientodelcancergastricoavanzado AT galindohector nuevasalternativaseneltratamientodelcancergastricoavanzado AT madridjorge nuevasalternativaseneltratamientodelcancergastricoavanzado AT sanchezcesar nuevasalternativaseneltratamientodelcancergastricoavanzado AT nervibruno nuevasalternativaseneltratamientodelcancergastricoavanzado AT alvarezmanuel nuevasalternativaseneltratamientodelcancergastricoavanzado AT orellanaeric nuevasalternativaseneltratamientodelcancergastricoavanzado
_version_	1718436348065480704

Nuevas alternativas en el tratamiento del cancer gástrico avanzado

Ejemplares similares